Robert I Blum Cytokinetics Inc (CYTK) insider trading activity

Robert I Blum is President & CEO of CYTOKINETICS INC. Currently has a direct ownership of 403,364 shares of CYTK, which is worth approximately $19.9 Million. The most recent transaction as insider was on Jul 22, 2021, when has been sold 5,000 shares (Common Stock) at a price of $29.82 per share, resulting in proceeds of $149,100. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 403K

1.49% 3M change

8.7% 12M change

Total Value Held $19.9 Million

Robert I Blum Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 22 2021	SELL Open market or private sale	$149,100 $29.82 p/Share	5,000 Reduced 1.38%	357,563 Common Stock
Jul 22 2021	BUY Exercise of conversion of derivative security	$31,500 $6.3 p/Share	5,000 Added 1.36%	362,563 Common Stock
Jul 06 2021	SELL Open market or private sale	$100,650 $20.13 p/Share	5,000 Reduced 1.38%	357,563 Common Stock
Jul 06 2021	BUY Exercise of conversion of derivative security	$31,500 $6.3 p/Share	5,000 Added 1.36%	362,563 Common Stock
Jun 18 2021	SELL Open market or private sale	$106,850 $21.37 p/Share	5,000 Reduced 1.38%	357,563 Common Stock
Jun 18 2021	BUY Exercise of conversion of derivative security	$31,500 $6.3 p/Share	5,000 Added 1.36%	362,563 Common Stock
Jun 03 2021	SELL Open market or private sale	$103,050 $20.61 p/Share	5,000 Reduced 1.38%	357,563 Common Stock
Jun 03 2021	BUY Exercise of conversion of derivative security	$31,500 $6.3 p/Share	5,000 Added 1.36%	362,563 Common Stock
May 20 2021	SELL Open market or private sale	$118,550 $23.71 p/Share	5,000 Reduced 1.38%	356,859 Common Stock
May 20 2021	BUY Exercise of conversion of derivative security	$31,500 $6.3 p/Share	5,000 Added 1.36%	361,859 Common Stock
May 07 2021	SELL Open market or private sale	$116,050 $23.21 p/Share	5,000 Reduced 1.38%	356,859 Common Stock
May 07 2021	BUY Exercise of conversion of derivative security	$31,500 $6.3 p/Share	5,000 Added 1.36%	361,859 Common Stock
Apr 30 2021	SELL Open market or private sale	$129,350 $25.87 p/Share	5,000 Reduced 1.38%	356,859 Common Stock
Apr 30 2021	BUY Exercise of conversion of derivative security	$31,500 $6.3 p/Share	5,000 Added 1.36%	361,859 Common Stock
Apr 12 2021	SELL Open market or private sale	$117,800 $23.56 p/Share	5,000 Reduced 1.38%	356,859 Common Stock
Apr 12 2021	BUY Exercise of conversion of derivative security	$31,500 $6.3 p/Share	5,000 Added 1.36%	361,859 Common Stock
Mar 22 2021	SELL Open market or private sale	$125,950 $25.19 p/Share	5,000 Reduced 1.38%	356,859 Common Stock
Mar 22 2021	BUY Exercise of conversion of derivative security	$30,750 $6.15 p/Share	5,000 Added 1.38%	357,425 Common Stock
Mar 08 2021	SELL Payment of exercise price or tax liability	$456,703 $19.19 p/Share	23,799 Reduced 6.25%	356,859 Common Stock
Mar 08 2021	SELL Open market or private sale	$97,450 $19.49 p/Share	5,000 Reduced 1.3%	380,658 Common Stock
Mar 08 2021	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.28%	385,658 Common Stock
Mar 02 2021	BUY Grant, award, or other acquisition	-	80,000 Added 17.37%	380,658 Common Stock
Mar 01 2021	SELL Payment of exercise price or tax liability	$194,949 $19.66 p/Share	9,916 Reduced 3.19%	300,658 Common Stock
Feb 26 2021	SELL Payment of exercise price or tax liability	$445,755 $18.73 p/Share	23,799 Reduced 7.12%	310,574 Common Stock
Feb 26 2021	SELL Open market or private sale	$96,650 $19.33 p/Share	5,000 Reduced 1.47%	334,373 Common Stock

Also insider at

GMDA

Gamida Cell Ltd. Healthcare

Director

RIB

Robert I Blum

President & CEO

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CYTK shares.

Notify only if

Value

Insider Trading

Get notified when an Cytokinetics Inc insider buys or sells CYTK shares.

Notify only if

Operation

Value

Type

News

Receive news related to CYTOKINETICS INC

Track Activities on CYTK

Account